Novo Nordisk® ncluding this presentation as well as the company’s statutory Annual Report 2019 and Form 20-F, f the Annual Report 2019, and written information released, or oral statements made, to the public in believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, uture operating or financial performance identify forward-looking statements. Examples of such Novo Nordisk’s products, product research, product development, product introductions and er share, capital expenditures, dividends, capital structure, net financials and other financial es such as legal proceedings, and d-looking statements involve inherent risks and uncertainties, both general and specific. Novo ould cause actual results to differ materially from those contemplated in any forward-looking d economic conditions, including interest rate and currency exchange rate fluctuations, delay or of supplies and production, product recalls, unexpected contract breaches or terminations, f competing products, reliance on information technology, Novo Nordisk’s ability to successfully ons, changes in governmental laws and related interpretation thereof, including on reimbursement, keting, perceived or actual failure to adhere to ethical marketing practices, investments in and recruit and retain the right employees, and failure to maintain a culture of compliance. the accuracy of forward-looking statements in this presentation, reference is made to the overview of ise any forward-looking statement after the distribution of this presentation, whether as a result of
Download PDF file